Biomatters has drafted in Karin Fredrikson as head of its expanded genomics software operations in New Jersey and San Fransisco.
Prior to Biomatters, Frederikson was director of business development for Roche subsidiary 454 Sequencing.
Biomatters' MD Brett Ammundsen said the decision to hire Fredrikson was made in preparation of the firm continuing product development for the interpretation of next generation sequencing (NGS) data.
He said: "The challenge in genomics right now is the sheer volume of data coming off NGS machines. Biomatters is committed to ensuring our customers are able to mine the full potential of this new wave of data, rather than becoming overwhelmed by it."
Seattle Genetics has named Chris Boerner as senior VP, commercial.
Boerner first joined the company in November 2010 as VP of marketing following a stint at Genentech.
He replaces Bruce Seeley, who said he is leaving the firm to “pursue other opportunities”.
Of the move, Clay Siegall, president and CEO of Seattle Genetics, said: “We anticipate a seamless transition as we continue to execute on our commercial priorities to deliver our Hodgkins lymphoma treatment ADCETRIS.”
Permeon Biologics has appointed Katherine Bowdish as president and chief scientific officer.
She joins the firm – which develops a novel class of intracellular protein biologics – after co-founding then serving as president and CEO of Anaphore. The firm focussed on the development of atrimers.
“Her proven expertise and success in leading and building innovative biotechnology companies are invaluable to Permeon as we continue to advance our novel intraphilin technology platform,” said John Edwards, executive chairman of Permeon.
Misfolded protein disease specialists Amorfix Life Sciences has hired Lynda Covello as VP of strategic alliances.
Prior to joining the team she was chair of LESI (Licensing Executives Society International), where she is still a member of the board.
She is also a member of the National Knowledge and Intellectual Property Management Task Force in the US.
Robert Gundel, Amorfix president and CEO said: "Ms. Covello is perfectly suited to execute Amorfix's strategy to partner its technology with companies that have complimentary capabilities, expertise and resources.”